SCHEMBL858211

SCHEMBL858211

COc1ccc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 3/20 0.71
KIT P10721 2/20 0.71
FGFR1 P11362 1/20 0.59
FGFR4 P22455 1/20 0.59
FLT3 P36888 2/20 0.56
DYRK1A Q13627 2/20 0.56
CDC7 O00311 1/20 0.56
DAPK3 O43293 1/20 0.56
ROCK2 O75116 1/20 0.56
PRKD3 O94806 1/20 0.56
MAP4K4 O95819 1/20 0.56
PAK4 O96013 1/20 0.56
PIM1 P11309 1/20 0.56
PRKACA P17612 1/20 0.56
CDK2 P24941 1/20 0.56
CSNK1A1 P48729 1/20 0.56
CLK2 P49760 1/20 0.56
GSK3B P49841 1/20 0.56
CDK7 P50613 1/20 0.56
CDK9 P50750 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1268011 0.89 CSF1R (0.68) CSF1RKITFGFR1FGFR4FLT3
SCHEMBL1266687 0.89 CSF1R (0.62) CSF1RKITFGFR1FGFR4FLT3
SCHEMBL1266936 0.88 CSF1R (0.67) CSF1RKITFGFR1FGFR4FLT3
SCHEMBL14213986 0.88 CSF1R (0.59) CSF1RKITFGFR1FGFR4FLT3
SCHEMBL1267581 0.88 CSF1R (0.75) CSF1RKITFGFR1FGFR4FLT3
SCHEMBL19898655 0.88 CSF1R (0.74) CSF1RKITFGFR1FGFR4FLT3
SCHEMBL878907 0.88 CSF1R (0.78) CSF1RKITFGFR1FGFR4FLT3
SCHEMBL1266737 0.87 CSF1R (0.60) CSF1RKITFGFR1FGFR4FLT3
SCHEMBL1266786 0.86 CYP3A4 (0.69) CSF1RKITFGFR1FGFR4FLT3
SCHEMBL12646996 0.86 CSF1R (0.78) CSF1RKITFGFR1FGFR4FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947708-B2 Compounds modulating C-kit activity PLEXXIKON, INC. (US) 2011-05-24 US claimed
US-20190263800-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON INC. 2019-08-29 US disclosed
US-20190263800-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON INC. 2019-08-29 US disclosed
US-20180111929-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC (US) 2018-04-26 US disclosed
US-20180111929-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC (US) 2018-04-26 US disclosed
US-20180055828-A1 KINASE MODULATION, AND INDICATIONS THEREFOR DAIICHI SANKYO, INC. 2018-03-01 US disclosed
US-20170247370-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON INC. 2017-08-31 US disclosed
US-20170247370-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON INC. 2017-08-31 US disclosed
US-9730918-B2 Kinase modulation, and indications therefor PLEXXIKON INC. (US) 2017-08-15 US disclosed
US-9550768-B2 Kinase modulation and indications therefor PLEXXIKON INC. (US) 2017-01-24 US disclosed
EP-1885723-A2 PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS PLEXXIKON, INC. (US) 2008-02-13 EP disclosed
EP-1755597-A2 AZAINDOLES MODULATING C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON, INC. (US) 2007-02-28 EP disclosed
US-20070032519-A1 Compounds modulating c-kit and c-fms activity and uses therefor PLEXXIKON, INC. 2007-02-08 US disclosed
US-20070032519-A1 Compounds modulating c-kit and c-fms activity and uses therefor PLEXXIKON, INC. 2007-02-08 US disclosed
US-20070032519-A1 Compounds modulating c-kit and c-fms activity and uses therefor PLEXXIKON, INC. 2007-02-08 US disclosed
WO-2007013896-A2 PYRROL (2,3-B) PYRIDINE DERIVATIVES PROTEIN KINASE INHIBITORS PLEXXIKON, INC. (US) 2007-02-01 WO disclosed
WO-2007013896-A2 PYRROL (2,3-B) PYRIDINE DERIVATIVES PROTEIN KINASE INHIBITORS PLEXXIKON, INC. (US) 2007-02-01 WO disclosed
WO-2007002433-A1 PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS PLEXXIKON, INC. (US) 2007-01-04 WO disclosed
US-20060058340-A1 Compounds modulating c-kit activity PLEXXIKON INC. 2006-03-16 US disclosed
WO-2006009755-A2 AZAINDOLES MODULATING C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON, INC. (US) 2006-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170247370-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR KIT, FLT3, FLT1 CSF1R 4/4885KIT 1/4885FGFR1 111/4885
US-20180111929-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, MAP3K13, MAP3K8 CSF1R 2023/4885KIT 1117/4885FGFR1 775/4885
US-20060058340-A1 Compounds modulating c-kit activity KIT, CDC7, CDK7 CSF1R 363/4885KIT 1/4885FGFR1 1715/4885
US-20180055828-A1 KINASE MODULATION, AND INDICATIONS THEREFOR FLT3, FLT4, FLT1 CSF1R 147/4885KIT 33/4885FGFR1 81/4885
US-20190263800-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR KIT, FLT3, FLT1 CSF1R 4/4885KIT 1/4885FGFR1 116/4885
US-20070032519-A1 Compounds modulating c-kit and c-fms activity and uses therefor KIT, FLT3, FLT1 CSF1R 7/4885KIT 1/4885FGFR1 113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.